US Patent Issued to Novartis on May 27 for "Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents" (Chinese, American Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,353, issued on May 27, was assigned to Novartis AG (Basel, Switzerland).

"Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents" was invented by Haibing Deng (Shanghai), Jinbiao Liu (Shanghai), Counde Oyang (Sunnyvale, Calif.), Ce Wang (Shanghai), Qitao Xiao (Shanghai), Guoliang Xun (Jiangsu, China) and Haiqiang Zeng (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions c...